PE20171800A1 - Produccion de vectores adeno-asociados de gran tamano - Google Patents

Produccion de vectores adeno-asociados de gran tamano

Info

Publication number
PE20171800A1
PE20171800A1 PE2017001997A PE2017001997A PE20171800A1 PE 20171800 A1 PE20171800 A1 PE 20171800A1 PE 2017001997 A PE2017001997 A PE 2017001997A PE 2017001997 A PE2017001997 A PE 2017001997A PE 20171800 A1 PE20171800 A1 PE 20171800A1
Authority
PE
Peru
Prior art keywords
adeno
aav
production
big size
associated vectors
Prior art date
Application number
PE2017001997A
Other languages
English (en)
Inventor
Sirkka Kyostio-Moore
David Souza
Karen Vincent
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56943906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171800(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PE20171800A1 publication Critical patent/PE20171800A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a metodos para producir una particula de virus adenoasociado (AAV) que contiene un genoma de AAV recombinante de gran tamano (por ejemplo, mayor de 4,7 kb). En algunos aspectos, la invencion proporciona particulas AAV y vectores de AAV que comprenden genomas de rAAV de gran tamano. Tambien se proporcionan lineas celulares productoras de particulas AAV que comprenden genomas de gran tamano
PE2017001997A 2015-04-08 2016-04-07 Produccion de vectores adeno-asociados de gran tamano PE20171800A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144862P 2015-04-08 2015-04-08
US201562220067P 2015-09-17 2015-09-17

Publications (1)

Publication Number Publication Date
PE20171800A1 true PE20171800A1 (es) 2017-12-28

Family

ID=56943906

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001997A PE20171800A1 (es) 2015-04-08 2016-04-07 Produccion de vectores adeno-asociados de gran tamano

Country Status (24)

Country Link
US (1) US10815497B2 (es)
EP (1) EP3280799A2 (es)
JP (3) JP6878299B2 (es)
KR (1) KR20170133500A (es)
CN (1) CN107864657A (es)
AU (3) AU2016245806A1 (es)
BR (1) BR112017021505A2 (es)
CA (1) CA2982123A1 (es)
CL (1) CL2017002537A1 (es)
CO (1) CO2017011344A2 (es)
CR (1) CR20170505A (es)
EA (1) EA201792236A1 (es)
EC (1) ECSP17074016A (es)
GT (1) GT201700214A (es)
HK (1) HK1246339A1 (es)
IL (3) IL283291B (es)
MX (1) MX2017012935A (es)
PE (1) PE20171800A1 (es)
PH (1) PH12017501836A1 (es)
SG (3) SG10201912912QA (es)
TN (1) TN2017000431A1 (es)
TW (1) TWI707951B (es)
UY (1) UY36611A (es)
WO (1) WO2016164609A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
BR112017009497A2 (pt) 2014-11-05 2018-02-06 Voyager Therapeutics, Inc. polinucleotídeos de aadc para o tratamento da doença de parkinson
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
MA42934A (fr) 2015-09-24 2018-08-01 Biomarin Pharm Inc Vecteurs de facteur viii à virus adéno-associé, particules virales associées et formulations thérapeutiques comprenant ceux-ci
ES2926585T3 (es) 2016-02-01 2022-10-27 Bioverativ Therapeutics Inc Genes de Factor VIII optimizados
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF DISEASES
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11518991B2 (en) 2017-02-24 2022-12-06 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated RASAL1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including RASAL1 in a subject
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2018213786A1 (en) * 2017-05-19 2018-11-22 Encoded Therapeutics, Inc. High activity regulatory elements
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
TWI804518B (zh) 2017-10-16 2023-06-11 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US20210338838A1 (en) * 2018-07-20 2021-11-04 University Of Utah Research Foundation Gene therapy for macular degeneration
KR20210076051A (ko) * 2018-10-12 2021-06-23 젠자임 코포레이션 간-특이적 유전자 대체 요법에 의한 중증 pku 치료를 위한 개선된 인간 pah의 생성
WO2021042004A1 (en) * 2019-08-29 2021-03-04 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting aav shedding
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN111218446B (zh) * 2019-12-25 2023-03-28 劲帆生物医药科技（武汉）有限公司 一种肝脏特异性启动子及其应用
US11254989B2 (en) * 2020-03-16 2022-02-22 The University Of North Carolina At Chapel Hill Compositions and methods for the selective detection of tumor-derived viral DNA
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
KR20230054840A (ko) 2020-07-30 2023-04-25 셰이프 테라퓨틱스 인코포레이티드 rAAV 비리온의 유도 생산을 위한 안정화된 세포주
US20220090130A1 (en) 2020-08-23 2022-03-24 Bioverativ Therapeutics Inc. MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
MX2024002333A (es) 2021-08-23 2024-03-07 Bioverativ Therapeutics Inc Sistema de expresion de baculovirus.
EP4392445A1 (en) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Closed-end dna production with inverted terminal repeat sequences
MX2024002334A (es) 2021-08-23 2024-05-23 Bioverativ Therapeutics Inc Genes optimizados del factor viii.
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
WO2001027303A1 (en) * 1999-10-12 2001-04-19 The University Of North Carolina At Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
EP1290205B1 (en) 2000-06-01 2006-03-01 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ618298A (en) 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20040092008A1 (en) * 2002-11-12 2004-05-13 Snyder Richard O. Recombinant AAV vectors for gene therapy of hemophilia A
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
ATE490307T1 (de) 2003-05-21 2010-12-15 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
PT3067417T (pt) 2009-06-16 2018-11-13 Genzyme Corp ¿métodos melhorados para puruficação de vetores aav recombinantes
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
JP6224459B2 (ja) 2011-02-17 2017-11-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法
DK2911687T3 (da) * 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
DK3044231T3 (da) * 2013-09-12 2020-09-07 Biomarin Pharm Inc Aav-vektorer, der omfatter en genkodningsfaktor viii primær anmodning
SG10201912977RA (en) 2014-05-02 2020-02-27 Genzyme Corp Aav vectors for retinal and cns gene therapy
LT3256594T (lt) 2015-02-10 2022-02-10 Genzyme Corporation Patobulintas virusinių dalelių tiekimas į dryžuotąjį kūną ir smegenų žievę
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造

Also Published As

Publication number Publication date
JP6878299B2 (ja) 2021-05-26
JP2023116678A (ja) 2023-08-22
TN2017000431A1 (en) 2019-04-12
ECSP17074016A (es) 2018-02-28
AU2022203942A1 (en) 2022-06-23
PH12017501836A1 (en) 2018-04-23
TWI707951B (zh) 2020-10-21
IL283291A (en) 2021-07-29
TW201710498A (zh) 2017-03-16
AU2016245806A1 (en) 2017-11-30
NZ737009A (en) 2024-01-26
SG10201909381WA (en) 2019-11-28
HK1246339A1 (zh) 2018-09-07
KR20170133500A (ko) 2017-12-05
IL294965A (en) 2022-09-01
US20190048362A1 (en) 2019-02-14
SG10201912912QA (en) 2020-02-27
EA201792236A1 (ru) 2018-03-30
US10815497B2 (en) 2020-10-27
UY36611A (es) 2016-11-30
MX2017012935A (es) 2018-02-12
CR20170505A (es) 2018-01-26
IL254933A0 (en) 2017-12-31
JP2021118724A (ja) 2021-08-12
IL283291B (en) 2022-08-01
AU2024201619A1 (en) 2024-03-28
JP2018510648A (ja) 2018-04-19
CL2017002537A1 (es) 2018-05-11
CN107864657A (zh) 2018-03-30
WO2016164609A2 (en) 2016-10-13
CA2982123A1 (en) 2016-10-13
GT201700214A (es) 2018-10-24
BR112017021505A2 (pt) 2018-07-03
SG11201708203UA (en) 2017-11-29
AU2022203942B2 (en) 2023-12-14
WO2016164609A3 (en) 2016-12-15
CO2017011344A2 (es) 2018-03-28
IL254933B (en) 2021-06-30
EP3280799A2 (en) 2018-02-14

Similar Documents

Publication Publication Date Title
PE20171800A1 (es) Produccion de vectores adeno-asociados de gran tamano
ZA201801657B (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
MX2022006652A (es) Proteinas de capside modificadas para un suministro mejorado de vectores de parvovirus.
IL263801A (en) Novel adeno-associated virus capsid proteins
SG10201913259QA (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
EP3262162A4 (en) Regulatable expression using adeno-associated virus (aav)
EP3177720A4 (en) Virus like particle comprising modified envelope protein e3
IL312792A (en) Methods for determining the serotype and heterogeneity of a viral particle and for improving the stability of RAAV particles and of AAV capsid protein variants, and the compositions containing them
UA120923C2 (uk) Молекула нуклеїнової кислоти, яка кодує капсидний протеїн aav5
WO2015109124A3 (en) Immunomodulatory agents
JP2017528075A5 (es)
EP3274707A4 (en) Evaluating biological material for unassociated virus-size particles of adenovirus or adeno-associated virus viral type
SG10201914029RA (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
DK3355915T3 (da) Vacciner af viruslignende partikel (vlp) af hundeparvovirus (cpv) og anvendelser deraf
IL273877A (en) Compounds consisting of an adenovirus-related virus for the purpose of restoring HBB gene activity and methods for their use
MA43925A (fr) Procã‰dã‰s de traitement du virus de l'hã‰patite b
DK3149165T3 (da) Kausative gener, der bibringer eddikesyretolerans i gær
JP2016538678A5 (es)
JP2016011847A5 (es)
JP2012248108A5 (es)
AR104216A1 (es) Producción de vectores adeno-asociados de gran tamaño
Cha Notre-Dame de Paris's Performance. experience contents-Current status of OSMU (OSMD) ${\rightarrow} $ MSMU. ASMD
JP2016051299A5 (es)